"instanceType","name","label","description","rationale","id","uuid:ID"
"StudyDesign","Study Design 1","","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","711cee9f-7f0e-456d-aba5-a9434396cb48"
